PLA2R-CAART

Targeted Depletion of Disease-Causing B Cells

PLA2R-CAART is being developed to treat patients with PLA2R-associated membranous nephropathy (MN), a B cell-mediated autoimmune disease that affects the kidneys. B cells produce autoantibodies, which are believed to form immune complexes that are deposited at the glomerular basement membrane, causing damage of the filtration barrier, and leading to proteinuria. Over time, PLA2R-associated MN may cause kidney failure and end-stage renal disease.

Other

Therapeutic Area Indication Program Discovery Preclinical Phase 1 Phase 2/3
Nephrology PLA2R Membranous Nephropathy PLA2R-CAART
Discovery in progress
Preclinical not started
Phase 1 not started
Phase 2/3 not started

1 In our discovery stage, we perform epitope mapping and optimize CAAR construct and design.

PLA2R-CAART Has Potential for Treatment of MN

PLA2R-CAART targets B cells that produce autoantibodies against phospholipase A2 receptor (PLA2R), a single-pass transmembrane protein expressed in the glomerulus of the kidney.

About Membranous Nephropathy

Primary MN is an immune-mediated kidney disease that affects approximately 15,000 patients in the United States and is associated with autoantibodies directed to PLA2R in 70-80% of patients. Since the discovery of anti-PLA2R autoantibodies in 2009, evidence has shown that these autoantibodies accumulate as immune complexes in the glomeruli of the kidney and damage the filtration barrier, leading to nephrotic syndrome as characterized by proteinuria. Many patients with PLA2R-associated MN are at risk for progression to kidney failure. Immunosuppressive therapies are commonly used, with rituximab increasingly employed to treat medium to high-risk patients. However, high unmet need remains as a significant fraction of patients either relapse or fail to respond following treatment with immunosuppressive therapies. We believe PLA2R-CAART could selectively deplete the PLA2R-autoantibody producing B cells that cause disease, providing a potentially safe, effective and durable therapeutic option for patients with PLA2R-associated MN.

PLA2R-CAAR Discovery

Discovery

Our PLA2R-CAART program is currently in the discovery phase. We are evaluating lead candidates containing the main immunogenic epitopes of PLA2R for demonstration of specific target engagement and cytolytic activity.

Posters & Publications

Learn more about our scientific research through posters at leading conferences and publications in peer-reviewed journals.

Examine Our Findings

Presentations

These posters and presentations hit the right notes.